The side-effects profile of novel drugs in chronic lymphocytic leukemia
The importance of the collaboration of the solid and liquid tumor communities
Developments in prognostic factors of acute myeloid leukemia (AML)
Gert J. Ossenkoppele
2 years on: Deborah discusses her venetoclax trial and becoming MRD negative
Deborah Henderson et al.
Graft versus host disease: how to treat it?